Expect to see Valeant Pharmaceuticals International Inc. (NYSE: VRS, TSX: VRX) continue to expand in the skincare sector via M&A.

The company is currently competing with Merz Pharma Group to buy Obagi Medical Products Inc. (Nasdaq: OMPI). Valeant announced on March 20 a $360 million deal with Obagi. On April 2, Greensboro, N.C.-based Merz offered about $380 million, sparking a bidding war with Valeant over the coveted skincare company. Merz wasn't aware that the target was also in discussions with Valeant.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.